Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Elangbam, C. S.
Right arrow Articles by Lightfoot, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elangbam, C. S.
Right arrow Articles by Lightfoot, R. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Peroxisome Proliferator-activated Receptors in Atherosclerosis and Inflammation—An Update

Chandikumar S. Elangbam

Department of Pathology, GlaxoWellcome Inc, Research Triangle Park, North Carolina 27709, cse63957{at}GlaxoWellcome.com

Ronald D. Tyler

Department of Toxicology, Medicines Safety Evaluation, GlaxoWellcome Inc, Research Triangle Park, North Carolina 27709

Ruth M. Lightfoot

Department of Toxicology, Medicines Safety Evaluation, GlaxoWellcome Inc, Research Triangle Park, North Carolina 27709

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor subfamily of transcription factors with pleiotropic effects on intra- and extracellular lipid metabolism, glucose homeostasis, cell proliferation, control of inflammation, and atherosclerosis. Three PPARs, namely {alpha}, {delta}, and {gamma} have been identifi ed with distinct tissue distribution patterns and metabolic functions. PPAR-{alpha} is predominantly expressed in brown adipose tissue, liver, kidney, duodenum, heart, skeletal muscle, and vascular endothelial cells and is involved in the control of lipoprotein metabolism, fatty acid oxidation, and the cellular uptake of fatty acids. PPAR-{gamma} is highly expressed in brown and white adipose tissues and, to lesser extent, in large intestine, retina, and some parts of the immune system, and plays a critical role in adipocyte differentiation and fat deposition. PPAR-{delta} shows a widespread tissue distribution but its regulation and functions are not yet known. Considerable evidence indicates that PPARs (PPAR-{alpha} and PPAR-{gamma} ) have beneficial effects in infl ammatory diseases, including atherosclerosis, through regulation of cytokine production, adhesion molecule expression on the endothelial cells, fi brinolysis, and modulation of monocyte-derived macrophages. In this review, the general and specific roles of the PPAR isotypes and their implications in the control of vascular inflammation and atherosclerosis are discussed.

Key Words: Adipocyte differentiation • atherosclerosis • chemokines • cytokines • inflammation • nuclear receptors • peroxisome proliferator-activated receptors.

References

  • Araki K., Yachi M., Hagisawa Y., Tanaka N., Isobe A., Sakakibara S., Ohsumi J., TsurutaF., Izumi T., Fujita T., Fujiwara T., Horikoshi H. (2000). Antidiabetic characterization of CS-011: A new thiazolidinedione with potent insulin-sensitizing activity. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association; June 9—13, San Antonio, Texas. Abstract 425.
  • Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou JP, Staels B., Auwerx J., Laville M., Vidal H. (1997). Tissue distribution and quantifi cation of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients. Diabetes 46: 1319—1327.[Abstract]
  • Benson S., Wu J., Padmanabhan S., Kurtz TW, Pershadsingh HA (2000). Peroxisome proliferator-activated receptor (PPAR)-{gamma} expression in human vascular smooth muscle cells: Inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-{gamma} activator Troglitazone. Am J Hypertens 13: 74—82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bisgaier CL, Essenburg AD, Barnett BC, Auerbach BJ, Haubenwallner S., Leff T., White AD, Creger P., Pape ME, Rea TJ, Newton RS (1998). A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res 39: 17—30.[Abstract/Free Full Text]
  • Bishop-Bailey D. (2000). Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129: 823—834.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bishop-Bailey D., Hla T. (1999). Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-{Delta} 12,14 prostaglandin J2. J Biol Chem 274: 17042—17048.[Abstract/Free Full Text]
  • Blanchard SG, Kliewer SA, Parks DJ, Way JM (2000). The novel tyrosine-based PPAR-gamma agonist GI262570 shows preferential binding to PPAR-gamma complexed with RXR-alpha and CBP. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association; June 9—13, San Antonio, Texas. Abstract 391.
  • Boisvert WA, Santiago R., Curtiss LK, Terkeltaub RA (1998). A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL-receptor defi cient mice. J Clin Invest 101: 353—363.[Web of Science][Medline] [Order article via Infotrieve]
  • Boring L., Gosling J., Chensue SW, Kunkel SL, Farese RVJr, Broxmeyer HE, Charo IF (1997). Impaired monocyte migration and reduced type I (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 100: 2552—2561.[Web of Science][Medline] [Order article via Infotrieve]
  • Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR{alpha}, β, and - {gamma} in the adult rat. Endocrinology 137: 354—366.[Abstract]
  • Brand K., Page S., Rogler G., Bartsch A., Brandl R., Knuechel R., Page M., Kaltschmidt C., Baeuerle PA, Neumeier D. (1996). Activated transcription factor nuclear factor-{kappa} B is present in the atherosclerotic lesion. J Clin Invest 97: 1715—1722.[Web of Science][Medline] [Order article via Infotrieve]
  • Bunte T., Hahman HW, Hellwig N., Hau U., Becker D., Dyckmans J., Keller HE, Schieffer HJ (1993). Effect of fenofi brate on angiographically examined coronary atherosclerosi s and left ventricular function in hypercholesterolemic patients. Atherosclerosis 98: 127—138.[Medline] [Order article via Infotrieve]
  • Chen N-G., Sarabia SF, Malloy PJ, Zhao X-Y., Feldman D., Reaven GM (1999). PPAR-{gamma} agonists enhance human vascular endothelial adhesivenes s by increasing ICAM-1 expression. Biochem Biophys Res Commun 263: 718—722.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chinetti G., Griglio S., Antonucci M., Torra IP, Delerive P., Majd Z., Fruchart J-C., Chapman J., Najib J., Staels B. (1998). Activation of proliferator-activated receptors {alpha} and {gamma} induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273: 25573—25580.[Abstract/Free Full Text]
  • Collins AR, Meehan WP, Hsueh WA, Palinski W., Law RE (2000). Troglitazone inhibits atherosclerotic lesion formation and macrophage accumulation in male LDLR-/- mice fed high fat and high fructose diets. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association; June 9—13, San Antonio, Texas. Abstract 221.
  • Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000). Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloidstimulated proinfl ammatory responses and neurotoxicity by PPARgamma agonists. JNeuroscience 20: 558—567.
  • Cominacini L., Garbin U., Pasini AF, Davoli A., Campagnola M., Rigoni A., Tosetti L., Lo Cascio V (1999). The expression of adhesion molecules on endothelial cells in inhibited by troglitazone through its antioxidant activity. Cell Adhesion Commun 7: 223—231.[Web of Science][Medline] [Order article via Infotrieve]
  • Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart JC, Najib J., Duriez P., Staels B. (1999). Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85: 394—402.[Abstract/Free Full Text]
  • Devchand PR, Keller H., Peters JM, Vazquez M., Gonzalez FJ, Wahli W. (1996). The PPAR-{alpha}-leukotriene B4 pathway to infl ammation control. Nature 384: 39—43.[CrossRef][Medline] [Order article via Infotrieve]
  • Djouadi F., Weinheimer CJ, Saffi tz JE, Pitchford C., Bastin J., Gonzalez FJ, Kelly DP (1998). A gender-related defect in lipid metabolism and glucose homeostasi s in peroxisome proliferator-activated receptor {alpha}-defi cient mice. J Clin Invest 102: 1083—1091.[Web of Science][Medline] [Order article via Infotrieve]
  • Ericsson CG, Hamsten A., Nilsson J., Grip L., Svane B., De Fair U. (1996). Angiographi c assessment of effects of bezafi brate on progression of coronary artery disease in young male postinfarction patients. Lancet 347: 849— 853.
  • Forman BM, Chen J., Evans RM (1997). Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors {alpha} and {delta}. Proc Natl Acad Sci USA 94: 4312—4317.[Abstract/Free Full Text]
  • Forman BM, Tontonoz P., Chen J., Brun RP, Spiegelman BM, Evans RM (1995). 15-Deoxy-{Delta}12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803—812.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Frick MH, Syvanne M., Nieminen MS, Kauma H., Majahalme S., Virtanen V., Kesaniemi YA, Pasternack A., Taskinen MR (1997). Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels in HDL cholesterol. Lopid Coronary Trial (LOCAT) study group. Circulation 96: 2137—2143.[Abstract/Free Full Text]
  • Goetze S., Xi XP, Graf K., Fleck E., Hsueh WA, Law RE (1999). Troglitazone inhibits angitensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett 452: 277—282.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Grossman SL, Lessem J. (1997). Mechanisms and clinical effects of thiazolidinediones. Exp Opin Invest Drugs 6: 1025—1040.[CrossRef]
  • Gu L., Okada Y., Clinton SK, Gerard C., Sukhova GK, Libby P., Rollins BJ (1998). Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2: 275— 281.
  • Hashimoto T., Fujita T., Usuda N., Cook W., Qi C., Peters JM, Gonzalez FJ, Yeldandi AV, Rao MS, Reddy JK (1999). Peroxisome and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor {alpha} and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem 274: 19228—19236.[Abstract/Free Full Text]
  • Hattori Y., Hattori S., Kasai K. (1999). Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells. Hypertension 33: 943—948.[Abstract/Free Full Text]
  • He T-C., Chan TA, Vogelstein B., Kinzler KW (1999). PPAR{delta} is an APCregulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335—345.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Inoue I., Shino K., Noji S., Awata T., Katayama S. (1998). Expression of peroxisome proliferator-activated receptor {alpha} (PPAR-{alpha}) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246: 370—374.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jiang C., Ting AT, Seed B. ( 1998). PPAR-gamma agonists inhibit production of monocyte infl ammatory cytokines. Nature 391: 82—86.[CrossRef][Medline] [Order article via Infotrieve]
  • Kato K., Satoh H., Endo Y., Yamada D., Midorikawa S., Sato W., Mizuno K., Fujita T., Tsukamoto K., Watanabe T. (1999). Thiazolidinediones down-regulate plasminogen activator inhibitor type-1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelialfunction. Biochem Biophys Res Commun 258: 431—435.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kelly LJ, Vicario PP, Thompson GM, Candelore MR, Doebber TW, Ventre J., Wu MS, Meurer R., Forrest MJ, Conner MW, Cascieri MA, Moller DE (1998). Peroxisome proliferator-activated receptors {gamma} and {alpha} mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology 139: 4920—4927.[Abstract/Free Full Text]
  • Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P., Wahli W., Willson TM, Lenhard JM, Lehmann JM (1997). Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors {alpha} and {gamma}. Proc Natl Acad Sci USA 94: 4318—4323.[Abstract/Free Full Text]
  • Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker MG, Wahli W. (1997). Fatty acids, eicosanoids, and hypolipidemic agents identifi ed as ligands of peroxisome proliferator-activated receptors by co-activator-dependen t receptor ligand assay. Mol Endocrinol 11: 779—791.[Abstract/Free Full Text]
  • Law RE, Goetze S., Xi XP, Jackson S., Kawano Y., Demer L., Fishbein MC, Meehan WP, Hsueh WA (2000). Expression and function of PPAR-{gamma} in rat and human vascular smooth muscle cells. Circulation 101: 1311—1318.[Abstract/Free Full Text]
  • Law RE, Meehan WP, Xi XP, GrafK., Wuthrich DA, Coats W., Faxon D., Hsueh WA (1996). Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98: 1897—1905.[Web of Science][Medline] [Order article via Infotrieve]
  • Leibowitz MD, Fievet C., Hennuyer N., Peinado-Onsurb e J., Duez H., Berger J., Cullinan CA, Sparrow CP, Baffi c J., Berger GD, Santini C., Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J. (2000). Activation of PPAR{delta} alters lipid metabolism in db/db mice. FEBS Lett 473: 333—336.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Li Y., Leung LK, Glauert HP, Spear BT (1996). Treatment of rats with the peroxisome proliferator ciprofi brate results in increased liver NF-{kappa}B activity. Carcinogenesis 17: 2305—2309.[Abstract/Free Full Text]
  • Lim H., Dey SK (2000). PPAR{delta} functions as a prostacyclin receptor in blastocyst implantation. TEM 11: 137—142.[Medline] [Order article via Infotrieve]
  • Lim H., Gupta RA, Ma W., Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM, Dey SK (1999). Cyclo-oxygenase-2-derive dprostacyclin mediates embryo implantation in the mouse via PPAR{delta}. Genes Dev 13: 1561—1574.[Abstract/Free Full Text]
  • Lin Q., Ruuska SE, Shaw NS, Dong D., Noy N. (1999). Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry 38: 185—190.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Loviscach M., Henry RR (1999). Clinical signifi cance of proliferator-activated receptors in health and disease. Medscape Diabetes Endocrinol 1—14.
  • Marx N., Bourcier T., Sukhova GK, Libby P., Plutzky J. (1999). PPAR-{gamma} activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR-{gamma} as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19: 546—551.[Abstract/Free Full Text]
  • Marx N., Mach F., Sauty A., Leung JH, Sarafi MN, Ransohoff RM, Libby P., Plutzky J., Luster AD (2000). Peroxisome proliferator-activated receptor-{gamma} activators inhibit IFN-{gamma} -induced expression of the T-cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164: 6503—6508.[Abstract/Free Full Text]
  • Marx N., Schonbeck U., Lazar MA, Libby P., Plutzky J. (1998). Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83: 1097—1103.[Abstract/Free Full Text]
  • Marx N., Sukhova GK, Collins T., Libby P., Plutzky J. (1999). PPAR{alpha} activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125—3131.[Abstract/Free Full Text]
  • Medicherla S., Dey D., Neogi P., Lakner FJ, Nag B. (2000). CLX-0921: A new PPAR-gamma agonist anti-diabetic thiazolidinedione compound. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association; June 9—13, San Antonio, Texas. Abstract 475.
  • Meertens LM, Miyata KS, Cechetto JD, Rachubinski RA, Capone JP (1998). A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPARalpha. EMBO J 17: 6972— 6978.
  • Michalik L., Wahli W. (1999). Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions. Curr Opin Biotechnol 10: 564— 570.
  • Miles PDG, Barak Y., He W., Evans RM, Olefsky JM (2000). Improved insulin-sensitivity in mice heterozygou s for PPAR-{gamma} defi ciency. J Clin Invest 105: 287—292.[Web of Science][Medline] [Order article via Infotrieve]
  • Minamikawa J., Tanaka S., Yamauchi M., Inoue D., Koshiyama H. (1998). Potent inhibitory effect of troglitazone on carotid arterial wall thicknes s in type-2 diabetes. J Clin Endocrinol Metab 83: 1818—1820.[Abstract/Free Full Text]
  • Mizushige K., Noma T., Yao L., Yu Y., Kiyomoto H., Hosomi N., Fukui T., Kimura S., Abe Y., Matsuo H. (2000). Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin-dependent diabetes mellitus of Otsuka Long-Evans Tokushima fatty rats. J Cardiovasc Pharmacol 35: 150—155.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Motojima K., Passilly P., Peters JM, Gonzalez FJ, Latruffe N. (1998). Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem 273: 16710—16714.[Abstract/Free Full Text]
  • Murao K., Imachi H., Momoi A., Sayo Y., Hosokawa H., Sato M., Ishida T., Takahara J. (1999). Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 454: 27—30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nag B. (2000). CLX-0901: A new class of orally active anti-diabetic compound. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association. Abstract 479.
  • Nagy L., Tontonoz P., Alvarez JGA, Chen H., Evans RM (1998). Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-{gamma}. Cell 93: 229—240.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Naitoh T., Nakabeppu H., Kamon J., Yotsumoto T., Kitahara M., Tsuruzoe N., Ohdoi K., Kato K., Suzuki M. (2000). NIP-221 is a novel and potent thiazolidinedione-base d peroxisome proliferator-activated receptor (PPAR) gamma ligand with long biological half-time. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association; June 9—13, San Antonio, Texas. Abstract 480.
  • Newby AC, Zaltsman AB (1999). Fibrous cap formation or destruction— The critical importance of vascular smooth muscle proliferation, migration, and matrix formation. Cardiovasc Res 41: 345—360.[Abstract/Free Full Text]
  • Nilakantan V., Spear BT, Glauert HP (1998). Liver-specifi c catalase expression in transgenic mice inhibits NF-kappa B activation and DNA synthesis induced by the peroxisome proliferator ciprofi brate. Carcinogenesis 19: 631—637.[Abstract/Free Full Text]
  • Ohta MY, Nagai Y., Takamura T., Nohara E., Kobayashi K. (2000). Inhibitory effect of troglitazone on tumor necrosis factor alpha-induced expression of monocyte chemoattractant protein-1 in human mesangial cells. Metabolism: Clin Exp 49: 163—166.
  • Pasceri V., Wu HD, Willerson JT, Yeh ETH (2000). Modulation of vascular infl ammation in vitro and in vivo by peroxisome proliferator-activated receptor-{gamma} activators. Circulation 101: 235—238.[Abstract/Free Full Text]
  • Plutzky J. (1999). Atherosclerotic plaque rupture: emerging insights and opportunities. Am J Cardiol 84: 15J—20J.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pulaski JT, Davis JA, Yuille K., Johnson JH (2000). The antidiabetic effects of CI-1037/CS011, a new thiazolidinedione. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association; June 9—13, San Antonio, Texas. Abstract 496.
  • Rajavashisth T., Qiao JH, Tripathi S., Tripathi J., Mishra N., Hua M., Wang XP, Loussararian A., Clinton S., Libby P., Lusis A. (1998). Heterozygous osteopetrotic (op) mutation reduces atherosclerosi s in LDL receptor-deficient mice. J Clin Invest 101: 2702—2710.[Web of Science][Medline] [Order article via Infotrieve]
  • Ricote M., Li AC, Willson TM, Kelly CJ, Glass CK (1998). The peroxisome proliferator-activate d receptor-gamm a is a negative regulator of macrophag e activation. Nature 391: 79—82.[CrossRef][Medline] [Order article via Infotrieve]
  • Rusyn I., Tsukamoto H., Thurman RG (1998). WY-14 643 rapidly activates nuclear factor kappaB in kupffer cells before hepatocytes. Carcinogenesis 19: 1217—1222.[Abstract/Free Full Text]
  • Schecter AD, Rollins BJ, Zhang YJ, Charo IF, Fallon JT, Rossikhina M., Giesen PL, Nemerson Y., Taubman MB (1997). Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 272: 28568—28573.[Abstract/Free Full Text]
  • Shibata T., Matsui K., Nagao K., Shinkai H., Yonemori F., Wakitani K. (1999). Pharmacological profi les of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol 364: 211—219.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shu H., Wong B., Zhou G., Li Y., Berger J., Woods JW, Wright SD, Cai T-Q. (2000). Activation of PPAR{alpha} or {gamma} reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocyte THP-1 cells. Biochem Biophys Res Commun 267: 345—349.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Spencer CM, Markham A. (1997). Troglitazone. Drugs 54: 89—101.[Web of Science][Medline] [Order article via Infotrieve]
  • Staels B., Auwerx J. (1998). Regulation of apo A-1 gene expression by fi brates. Atherosclerosis 137: S19—S23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Staels B., Dallongeville J., Auwerx J., Schoonjans K., LeitersdorfE., Fruchart JC (1998). Mechanism of action of fi brates on lipid and lipoprotein metabolism. Circulation 98: 2088—2093.[Abstract/Free Full Text]
  • Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra IP, Delerive P., Faddel A., Chinetti G., Fruchart JC, Najib J., Maclouf J., Tedgui A. (1998). Activation of human aortic smooth muscle cells is inhibited by PPAR{alpha} but not by PPARβ activattors. Nature 393: 790—793.[CrossRef][Medline] [Order article via Infotrieve]
  • Su CG, Wen X., Bailey ST, Jiang W., Rangwala SM, Keilbaugh SA, Flanigan A., Murthy S., Lazar MA, Mitchell A., Wu GD (1999). A novel therapy for colitis utilizing PPAR-{gamma} ligands to inhibit the epithelial infl ammatory response. J Clin Invest 104: 383—389.[Web of Science][Medline] [Order article via Infotrieve]
  • Takagi T., Yoshida K., Akasaka T., Hozumi T., Yamamuro A., Morioka S. (1999). Troglitazone reduces intimal hyperplasia after coronary stent implantation in patients with type 2 diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 33: 100A.
  • Thieringer R., Fenyk-Melody JE, Le Grand CB, Shelton BA, Detmers PA, Somers EP, Carbin L., Moller DE, Wright SD, Berger J. (2000). Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol 164: 1046—1054.[Abstract/Free Full Text]
  • Tontonoz P., Nagy L., Avarez JGA, Thomazy VA, Evans RM (1998). PPAR{gamma} promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241—252.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 29, No. 2, 224-231 (2001)
DOI: 10.1080/019262301317052495
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
C. S. Elangbam, T. A. Brodie, H. Roger Brown, J. B. Nold, T. J. Raczniak, R. D. Tyler, R. M. Lightfoot, and H. G. Wall
Vascular Effects of GI262570X (PPAR-{gamma} agonist) in the Brown Adipose Tissue of Han Wistar Rats: A Review of 1-month, 13-week, 27-week and 2-year Oral Toxicity Studies
Toxicol Pathol, June 1, 2002; 30(4): 420 - 426.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Elangbam, C. S.
Right arrow Articles by Lightfoot, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elangbam, C. S.
Right arrow Articles by Lightfoot, R. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?